DDInter708 DDInter1676
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ezogabine {u} (Compound) resembles {v} (Compound) Flupirtine
Ezogabine {u} (Compound) binds {v} (Gene) UGT1A1
Ezogabine {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Openers
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ezogabine (Compound) resembles Flupirtine (Compound)
Ezogabine (Compound) binds UGT1A1 (Gene)
Ezogabine (Compound) is included by Potassium Channel Openers (Pharmacologic Class)
Ezogabine (Compound) causes Ill-defined disorder (Side Effect)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ezogabine may lead to a major life threatening interaction when taken with Nilotinib
Ezogabine may lead to a major life threatening interaction when taken with Crizotinib